Search

Your search keyword '"Katherine, Zukotynski"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Katherine, Zukotynski" Remove constraint Author: "Katherine, Zukotynski"
149 results on '"Katherine, Zukotynski"'

Search Results

2. Free water levels in normal-appearing white matter predict vascular lesion progression in individuals with dementia

3. Wavelet phase coherence of ictal scalp EEG-extracted muscle activity (SMA) as a biomarker for sudden unexpected death in epilepsy (SUDEP).

4. EFFECTS OF VASCULAR BURDEN ON COGNITION ARE MEDIATED BY ATROPHY, AMYLOID, AND GLUCOSE METABOLISM: A MULTI-CENTRE MIXED COHORT OF SMALL VESSEL DISEASE AND ALZHEIMER'S PATHOLOGY

5. A brief overview of targeted radionuclide therapy trials in 2022

6. Ictal ECG-based assessment of sudden unexpected death in epilepsy

7. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

8. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

9. Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI

10. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

11. ACR Appropriateness Criteria® Right Upper Quadrant Pain: 2022 Update

12. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging

13. Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial

14. CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

15. ACR Appropriateness Criteria® Right Lower Quadrant Pain: 2022 Update

16. Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET

17. Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)

20. Evidence-Based Artificial Intelligence in Medical Imaging

21. Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI

23. Role of Artificial Intelligence in Theranostics

24. Update on Molecular Imaging and Precision Medicine in Lung Cancer

25. Management of Differentiated Thyroid Cancer: The Standard of Care

26. Detecting lumbar lesions in 99m Tc‐MDP SPECT by deep learning: Comparison with physicians

27. Exploratory Assessment of K-means Clustering to Classify 18F-Flutemetamol Brain PET as Positive or Negative

28. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide

29. International Impact of COVID-19 on the Diagnosis of Heart Disease

30. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

31. Beyond the

32. Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography

33. Machine Learning in Nuclear Medicine: Part 2—Neural Networks and Clinical Aspects

34. Amyloid‐independent vascular contributions to cortical atrophy and cognition in a multi‐center mixed cohort with low to severe small vessel disease

35. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects

36. Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies

37. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)

38. Prostate Cancer Lymphangitic Pulmonary Carcinomatosis

39. Clinical and Technical Considerations for Brain PET Imaging for Dementia

40. The Use of Random Forests to Classify Amyloid Brain PET

41. Machine Learning in Nuclear Medicine: Part 1—Introduction

42. Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network

43. Case - Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation

44. Detecting lumbar lesions in

45. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

46. Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82

47. A Radiology-focused Review of Predictive Uncertainty for AI Interpretability in Computer-assisted Segmentation

48. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy

49. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

50. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide

Catalog

Books, media, physical & digital resources